CMA
ACAD icon

Cedar Mountain Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Cedar Mountain Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.79K Hold
308
– – ﹤0.01% 565
2026
Q1 		$6.86K Buy
+308
New +$7.36K ﹤0.01% 557

Other funds holding ACAD

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Cedar Mountain Advisors's ACAD Position: Q2 2026 in Review

Cedar Mountain Advisors held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 308 shares worth $7.79K. The position accounts for ﹤0.01% of the portfolio, ranked #565.

Cedar Mountain Advisors first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 36 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Cedar Mountain Advisors held 308 shares of Acadia Pharmaceuticals worth $7.79K as of Q2 2026.
  • Cedar Mountain Advisors left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #565 holding.
  • Cedar Mountain Advisors first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 36 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.